Enliven Therapeutics

What Enliven Therapeutics does

Enliven Therapeutics is a clinical-stage precision oncology biopharmaceutical company developing small molecule kinase inhibitors designed to address treatment resistance, tolerability limitations, and combination challenges in cancer therapy. The company's pipeline centers on three assets: ELVN-001, a potent and highly selective ATP-competitive BCR::ABL1 inhibitor that binds a unique P-loop "folded-in" active conformation of ABL1 to create a narrow selectivity tunnel and retain activity against mutations such as T315I that confer resistance to most approved TKIs; ELVN-002, a selective HER2 inhibitor with a differentiated binding mode being evaluated in combination with HER2-targeting antibody-drug conjugates (ado-trastuzumab emtansine and trastuzumab deruxtecan); and ELV-3111, a Type 1 pan-RAF inhibitor engineered to combine safely with MEK inhibitors for NRAS and BRAF mutant cancers. The company's primary patient populations are chronic myeloid leukemia patients who are resistant, refractory, or intolerant to existing tyrosine kinase inhibitors, and patients with HER2+ and HER2 mutant solid tumors.

Enliven was founded in 2019-2020 and became a public company in February 2023 through a reverse merger acquisition of IMARA Inc. for approximately $340 million, trading on NASDAQ under ticker ELVN. The company relocated its corporate headquarters from Boulder, Colorado to Burlingame, California in June 2026 while retaining early-stage research operations in Boulder, and currently has 51-100 employees. The company is led by CEO Rick Fair (appointed December 11, 2025), co-founders Sam Kintz (Head of Pipeline), Joe Lyssikatos (Research Fellow), and Anish Patel (Chief Operating Officer), with scientific advisors including Brian Druker, the developer of Gleevec, and Kevin Koch, co-founder of Array BioPharma. Phase 1b data for ELVN-001 demonstrated a 61% major molecular response rate at 80mg once-daily, 67% MMR in patients with 1-2 prior TKIs, and a favorable safety profile with only 6% discontinuation due to adverse events, supporting advancement to a Phase 3 pivotal trial (ENABLE-2) in the second half of 2026.

Enliven's business model is pharmaceutical drug development and commercialization. As a pre-revenue clinical-stage company, it funds operations through equity financings, having raised approximately $85M in Series B (December 2020), $90M in a private placement (March 2024), and $460M in an upsized public offering (June 2026). The company held $452.4M in cash and marketable securities as of Q1 2026, providing runway into early 2029, and had a market valuation of approximately $3 billion as of June 2026. Revenue will be generated through pharmaceutical product sales via specialty pharmacies, hospital buying groups, and direct physician prescribing upon regulatory approval of its lead candidates.

Name

Enliven Therapeutics

Legal name

Enliven Therapeutics, Inc.

Website

https://enliventherapeutics.com

Company type

Public

Founded year

2020

Operating status

Operating

Headcount range

51–100 employees

Short description

Enliven Therapeutics is a clinical-stage precision oncology company developing selective small molecule kinase inhibitors for cancer, with lead candidate ELVN-001 targeting BCR::ABL1 in chronic myeloid leukemia patients resistant to existing TKIs, and trades on NASDAQ as ELVN.

Ownership category

akta.pro rank

Product category

Precision Oncology Therapeutics

NAICS

Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

CAR-T & TCR-T Therapies (HLAAABAC)

Keywords

• Precision oncology therapeutics
• Small molecule kinase inhibitors
• Cancer drug development
• Clinical-stage biopharmaceuticals
• Targeted oncology therapies

Headquarters

HQ city

Boulder

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Others

Revenue model

1. Drug Development and Commercialization: Enliven Therapeutics is a clinical-stage biopharmaceutical company in pre-revenue phase. The company is developing small molecule therapeutics for precision oncology. ELVN-001 is in Phase 1 clinical trials for chronic myeloid leukemia and is preparing for Phase 3 pivotal trial (ENABLE-2) in H2 2026. Revenue will be generated through pharmaceutical product sales upon regulatory approval and commercialization.

Go-to-market motion1 record

Marketing channels6 records

Core offering

Enliven Therapeutics is a clinical-stage biopharmaceutical company developing small molecule kinase inhibitors for precision oncology. The company's pipeline includes three lead product candidates: ELVN-001 (a selective BCR::ABL1 inhibitor for chronic myeloid leukemia), ELVN-002 (a selective HER2 inhibitor for HER2+ solid tumors), and ELV-3111 (a type 1 pan-RAF inhibitor for NRAS and BRAF mutant cancers). Enliven is preparing ELVN-001 for a Phase 3 pivotal trial (ENABLE-2) in the second half of 2026.

Product overview

Enliven Therapeutics is a clinical-stage biopharmaceutical company developing small molecule therapeutics for precision oncology. The company's pipeline consists of three lead product candidates: ELVN-001 (a BCR::ABL1 kinase inhibitor for chronic myeloid leukemia in Phase 1/3 development), ELVN-002 (a HER2 inhibitor for HER2+ solid tumors in Phase 1), and ELV-3111 (a pan-RAF inhibitor for NRAS/BRAF mutant cancers in preclinical/early development). The company acquired IMARA Inc. in February 2023 through a reverse merger.

Differentiator

Problem solved

Functional benefit

Products and services

• ELVN-001 ELVN-001 is a potent, highly selective small molecule kinase inhibitor designed to target the BCR-ABL gene fusion for patients with chronic myeloid leukemia (CML). It targets the ATP-binding site of the ABL1 kinase domain and binds to a unique P-loop 'folded-in' active conformation, creating a narrow selectivity tunnel. It is designed to have activity against emerging mutations (including T315I) that confer resistance to allosteric TKIs such as asciminib, while avoiding off-target activity that may cause adverse events.
• ELVN-002 ELVN-002 is a potent, selective HER2 inhibitor with a differentiated binding mode conferring the potential for enhanced efficacy in combination with HER2-targeting antibody-drug conjugates. It is being evaluated in Phase 1 trials in people with HER2+ and HER2 mutant tumors, including HER2+ metastatic breast cancer and HER2+ NSCLC.
• ELV-3111 ELV-3111 is a type 1 pan-RAF inhibitor that is designed to safely combine with MEK inhibitors for enhanced anti-tumor activity in NRAS and BRAF mutant cancers, including the most common mechanisms of BRAF inhibitor clinical resistance.

Quantifiable outcome

• 61% overall major molecular response (MMR) rate with 80mg once daily dose of ELVN-001
• +5 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered major.

• IMARA Inc.majorStrategic or Co-development Partner · 23 February 2023Enliven Therapeutics completed the acquisition of IMARA Inc. for approximately $340 million through a reverse merger transaction on February 23, 2023. This acquisition expanded Enliven's pipeline and capabilities in the rare disease and oncology space.
• IMARA Inc.majorStrategic or Co-development Partner · 14 October 2022IMARA Inc., a Boston-based rare disease specialist, announced a planned merger with Enliven Therapeutics in October 2022. The transaction combined two clinical-stage companies to create a larger oncology-focused entity.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Blueprint Medicines: Clinical-stage precision oncology company developing selective kinase inhibitors (e.g., Ayvakit, Gavreto). Directly comparable to Enliven in business model, therapeutic area, and target class, with both companies leveraging structure-based drug design to develop differentiated kinase inhibitors.
• Nuvalent: Precision oncology company developing selective small molecule kinase inhibitors (NVL-520 for ROS1, zidesamtinib for HER2). Directly comparable to Enliven given shared focus on selectivity-driven kinase inhibitors for validated oncology targets.
• Cogent Biosciences: Clinical-stage precision oncology company developing kinase inhibitors including bezuclastinib for systemic mastocytosis. Comparable as a small-cap, clinical-stage precision oncology company focused on kinase inhibitors with similar commercial scale.
• Revolution Medicines: Precision oncology company developing targeted therapies including RAS(ON) inhibitors. Directly comparable in business model and precision oncology focus, with a similar pipeline-stage profile targeting validated oncology drivers.
• Kronos Bio: Clinical-stage oncology company developing small molecule therapies targeting dysregulated transcription factors and kinase pathways. Comparable as a small-cap clinical oncology company with multiple early-stage programs.
• Rigel Pharmaceuticals: Commercial-stage hematology/oncology company with approved CML therapy Rezlidhia (olutasidenib) and Tavalisse. Relevant CML competitor and comparable in therapeutic area, though at a later commercial stage than Enliven.
• Theseus Pharmaceuticals: Clinical-stage oncology company developing kinase inhibitors including THE-349 for BCR-ABL1 (CML). Directly comparable to ELVN-001 as a CML-focused kinase inhibitor developer using structure-based design.

Emerging players

• Foghorn Therapeutics: Clinical-stage precision oncology company developing therapies targeting the chromatin regulatory system. Comparable as a small-cap, clinical-stage precision oncology company with similar financing scale and pipeline structure.
• Terns Pharmaceuticals: Clinical-stage biopharmaceutical company developing small molecule therapies for oncology and metabolic disease. Comparable as a small-cap clinical-stage biotech with similar platform approach to small molecule drug development.

Broad incumbents

• Novartis: Global pharmaceutical company with marketed CML therapies including Tasigna (nilotinib) and Scemblix (asciminib). Relevant broad incumbent competing with ELVN-001 in CML with established commercial and clinical infrastructure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/enliventherapeutics
• Xx.com/enliven_tx

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds6 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Enliven Therapeutics